Keyphrases
Europe
41%
HIV Patients
37%
HIV-positive
33%
Antiretroviral Therapy
33%
EuroSIDA
27%
CD4 Count
27%
Confidence Interval
27%
Donor-acceptor
26%
Combined Antiretroviral Therapy (cART)
24%
AIDS/HIV
22%
D Study
21%
Eastern Europe
20%
People Living with HIV (PLHIV)
19%
Tuberculosis
16%
Highly Active Antiretroviral Therapy (HAART)
12%
Myocardial Infarction
12%
Antiviral Drugs
11%
HIV Infection
10%
Viral Load
10%
Chronic Kidney Disease
10%
Estimated Glomerular Filtration Rate
10%
Virological Failure
10%
Western Europe
10%
Adverse Events
10%
COVID-19
9%
Incidence Rate
9%
Abacavir
9%
Risk Factors
9%
Non-AIDS Comorbidities
8%
Multidrug-resistant Tuberculosis (MDR-TB)
7%
Protease Inhibitors
7%
Cardiovascular Risk
7%
Hepatitis C
6%
HIV RNA
6%
Infected Patients
6%
Anti-HIV Drugs
6%
AIDS-defining Illness
6%
Cardiovascular Disease
6%
Co-infected Patients
6%
All-cause Mortality
6%
Antiretroviral
6%
Cause of Death
5%
Latin America (LATAM)
5%
Hepatitis C Virus
5%
Antiretroviral Therapy Initiation
5%
Pneumocystis Jirovecii
5%
HIV Care
5%
Human Immunodeficiency Virus Type 1 (HIV-1)
5%
Healthcare
5%
Mortality Rate
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Cohort Study
18%
Adverse Event
13%
Infection
11%
Cardiovascular Disease
11%
Heart Infarction
10%
Chronic Kidney Failure
10%
Anti-Human Immunodeficiency Virus
9%
Proteinase Inhibitor
8%
Abacavir
8%
Hepatitis C
7%
Hepatitis C Virus
7%
Multi-Drug-Resistant Tuberculosis
6%
Disease
6%
Human Immunodeficiency Virus Infection
6%
Mixed Infection
5%
Malignant Neoplasm
5%
Viremia
5%
Medicine and Dentistry
Human Immunodeficiency Virus
82%
Antiretroviral Therapy
25%
Cohort Analysis
16%
COVID-19
9%
Infection
8%
Cardiovascular Disease
7%
Cell Count
7%
Chronic Kidney Disease
7%
Human Immunodeficiency Virus Infection
7%
Multidrug Resistant Tuberculosis
5%
Hepatitis C
5%
